| Date Filed | Type | Description |
| 10/12/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/06/2023 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 9.9% stake in Vistagen Therapeutics, Inc. |
| 10/05/2023 |
SC 13G
| Point72 Asset Management, L.P. reports a 5.6% stake in Vistagen Therapeutics, Inc. |
| 10/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ... |
| 10/03/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 10/02/2023 |
8-K
| Quarterly results |
| 09/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 08/22/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/09/2023 |
SC 13G
| COMMODORE CAPITAL LP reports a 19.7% stake in Vistagen Therapeutics, Inc. |
| 08/08/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/07/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 07/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/18/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/13/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 0% stake in VistaGen Therapeutics, Inc. |
| 07/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/30/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/28/2023 |
10-K
| Annual Report for the period ended March 31, 2023 |
| 06/28/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 06/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/01/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 04/19/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/23/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/22/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/17/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 03/08/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/07/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 03/02/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 0% stake in VistaGen Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 0% stake in VistaGen Therapeutics, Inc. |
|